Gamida Cell Announces Launch of Public Offering of Ordinary Shares
December 16 2020 - 9:03PM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious
hematologic diseases, today announced the launch of a follow-on
public offering of its ordinary shares. In addition, Gamida Cell
expects to grant the underwriters a 30-day option to purchase up to
an additional 15% of the ordinary shares to be sold in the offering
on the same terms and conditions. The offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed. All of the shares in the
offering are to be sold by Gamida Cell.
Gamida Cell intends to use the net proceeds from this offering,
together with its existing cash and cash equivalents, available for
sale and short-term deposits: to fund (i) the preparation of a
potential commercial launch of omidubicel; (ii) the continued
clinical development of its product candidates, including GDA-201;
(iii) the expansion of its commercial manufacturing capabilities;
and (iv) general corporate purposes, including general and
administrative expenses and working capital.
Piper Sandler & Co., Evercore Group L.L.C. and JMP
Securities LLC are acting as joint book-running managers for this
offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission on Form F-3 (File
No. 333-234701) and declared effective on November 27, 2019. This
offering will be made only by means of a prospectus supplement.
Copies of the preliminary prospectus supplement and the
accompanying prospectus related to this offering may be obtained,
when available, from: Piper Sandler & Co., 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924 or by email at
prospectus@psc.com; Evercore Group L.L.C., 55 East 52nd Street, New
York, New York 10055, Attention: Equity Capital Markets, by
telephone: (888) 474-0200, or by email:
ecm.prospectus@evercore.com; or JMP Securities LLC, 600 Montgomery
Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus
Department, by calling (415) 835-8985 or by email at
syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to
cures for blood cancers and serious blood diseases. We harness our
cell expansion platform to create therapies with the potential to
redefine standards of care in areas of serious medical need.
Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the timing, size and use of
proceeds of the offering described herein, and its expectations
with respect to granting the underwriters a 30-day option to
purchase additional ordinary shares. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those that are described in the Risk Factors
sections of the preliminary prospectus supplement for such offering
to be filed with the SEC, and the documents incorporated by
reference therein, including without limitation the Company’s
Annual Report on Form 20-F filed with the SEC on February 26, 2020,
the accompanying prospectus and other filings that Gamida Cell
makes with the SEC from time to time (which are available at
http://www.sec.gov), which could cause the events and circumstances
discussed in such forward-looking statements not occur on the terms
described or at all. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date hereof. Gamida Cell undertakes no
obligation to update any such forward-looking statements after the
date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201216006066/en/
Investor: Stephanie Ascher Stern Investor Relations, Inc.
stephanie.ascher@sternir.com 1-212-362-1200
Media Inquiries: Matthew Corcoran Ten Bridge
Communications mcorcoran@tenbridgecommunications.com
1-617-866-7350
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024